Price
$82.35+7.45%Social Signal Score
Analyst Ratings
36 analystsRevenue
$789.61M+482.09%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Keith W. Pfeil
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 6,000
- Beta
- 0.96
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 10.24
Financials
Revenue
$789.61M+482.1%Net Income
$151.57M+477.9%EBITDA
$189.82M+313.6%Free Cash Flow
$176.57M+399.1%EPS (diluted)
$1.10+307.4%Shares Outstanding (diluted)
138.19M+43.2%Operating Expenses
$323.14MCash & Debt
$595.14MReturn of Capital
$136.06MRevenue by Segment (annual)
$2.52BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.94B | $537.90M | $3.98 |
| 2024 | $2.52B | $102.98M | $0.76 |
| 2023 | $1.57B | $122.87M | $1.09 |
| 2022 | $1.02B | $190.17M | $1.89 |
| 2021 | $958.10M | $149.19M | $1.48 |
| 2020 | $789.04M | $102.28M | $1.04 |
| 2019 | $785.37M | $155.21M | $1.57 |
| 2018 | $712.97M | $156.47M | $1.60 |
| 2017 | $635.98M | $107.35M | $1.12 |
| 2016 | $563.99M | $104.34M | $1.09 |
| 2015 | $544.75M | $112.78M | $1.19 |
| 2014 | $474.37M | $92.48M | $0.98 |
| 2013 | $434.46M | $68.61M | $0.74 |
| 2012 | $385.99M | $73.83M | $0.82 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from GMED's reported EPS growth of 12.9% a year over 13 years.
- EPS in 5 years
- $7.30
- Implied price
- $160.61
- Return from $75.60
- 16.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $79.85 — today's price is already 5.3% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 16 | 19 | 22 | 25 | 28 |
|---|---|---|---|---|---|
| 2.9% | -0.6% | 2.9% | 6.0% | 8.7% | 11.2% |
| 7.9% | 4.3% | 7.9% | 11.1% | 14.0% | 16.6% |
| 12.9% | 9.1% | 12.9% | 16.3% | 19.3% | 22.0% |
| 17.9% | 13.9% | 17.9% | 21.4% | 24.6% | 27.4% |
| 22.9% | 18.8% | 22.9% | 26.6% | 29.8% | 32.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-50.00%Social Signal Score
Mentions (23)
- Newszacks.com·5h ago·Neutral
Zacks Industry Outlook Globus Medical, Intuitive Surgical and Thermo Fisher Scientific Globus Medical, Intuitive Surgical and Thermo Fisher Scientific have been highlighted in this Industry Outlook article.
View source ↗ - Newszacks.com·21h ago·Positive
Here's Why Globus Medical (GMED) is a Strong Value Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View source ↗ - Newszacks.com·21h ago·Neutral
3 Medical Instruments Stocks Using GenAI to Navigate Industry Woes GenAI offers growth opportunities for GMED, ISRG and TMO, but evolving regulations and industry risks are likely to shape adoption.
View source ↗ - Newszacks.com·5d ago·Neutral
GMED vs. ITGR: Which Stock Is the Better Value Option? Investors interested in Medical - Instruments stocks are likely familiar with Globus Medical (GMED) and Integer (ITGR). But which of these two stocks offers value investors a better bang for their buck right now?
View source ↗ - Newsprnewswire.com·6d ago·Neutral
Top Los Angeles Spine Surgeon Dr. Albert Wong Served as Faculty Leader at Advanced Spine Surgery Cadaver Training Courses for SeaSpine and Globus Renowned neurosurgeon Dr. Albert Wong of DOCS Health served as faculty leader at two hands-on cadaver training courses in 2026, teaching minimally invasive
View source ↗ - Newszacks.com·19d ago·Positive
What Makes Globus Medical (GMED) a New Strong Buy Stock Globus Medical (GMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
View source ↗ - Newszacks.com·26d ago·Neutral
3 Medical Instruments Stocks Banking on GenAI to Tackle Industry Woes GenAI offers growth potential for VCYT, GMED and UFPT, but regulatory and technology risks are likely to challenge adoption across healthcare.
View source ↗ - News (RSS)economictimes·30d ago·Positive
Dividend stocks: Kalyan Jewellers, IREDA among over 150 stocks turning ex-record date this week. Do you own any? More than 150 companies, including Kalyan Jewellers, IREDA, Zee Entertainment Enterprises, NSDL and others have scheduled record dates for dividends during the week of September 7 (Monday) to September 11 (Friday).To be eligible for these corporate actions, investors must hold the shares in their demat accounts as of the respective record dates. The list is tentative, as more companie
View source ↗ - Newsprnewswire.com·32d ago·Neutral
YSL BEAUTY IST WIEDER DA - DIE „BLOCK PARTY"-SERIE KOMMT NACH LONDON /PRNewswire/ -- Nach dem gefeierten Auftakt in Madrid und einer Reihe bahnbrechender Veranstaltungen rund um den Globus ist YSL Beauty nun mit der mit Spannung
View source ↗ - News (RSS)investing·32d ago·Neutral
Globus Medical receives CE mark for Excelsius3D imaging system
View source ↗ - Newsglobenewswire.com·32d ago·Neutral
Globus Medical Announces CE Mark for Excelsius3D™ Imaging System Excelsius3D™ – Intelligent 3-in-1 Imaging System Expands Excelsius™ Ecosystem in the European Union Excelsius3D™ – Intelligent 3-in-1 Imaging System Expands Excelsius™ Ecosystem in the European Union
View source ↗ - Newszacks.com·33d ago·Positive
3 Reasons Growth Investors Will Love Globus Medical (GMED) Globus Medical (GMED) could produce exceptional returns because of its solid growth attributes.
View source ↗ - Newszacks.com·38d ago·Positive
Wall Street Analysts Believe Globus Medical (GMED) Could Rally 25.03%: Here's is How to Trade The mean of analysts' price targets for Globus Medical (GMED) points to a 25% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
View source ↗ - Newszacks.com·39d ago·Neutral
GMED or ITGR: Which Is the Better Value Stock Right Now? Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or Integer (ITGR). But which of these two stocks is more attractive to value investors?
View source ↗ - Newszacks.com·39d ago·Positive
Globus Medical (GMED) is a Top-Ranked Momentum Stock: Should You Buy? Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗ - Newsglobenewswire.com·40d ago·Negative
…Higgs Boson Health to Transform Healthcare Experience Through AI-Driven Digital Solutions AUDUBON, Pa., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced the acquisition of Higgs Boson Health, a digital healthcare experience company based in Durham, NC and incubated out of Duke University. With a mission to transform healthcare experience through digital innovation, Higgs Boson will position Globus Medical to shape …
View source ↗ - News (Marketaux)seekingalpha.com·47d ago·Neutral
Globus Medical: The Dip Makes It Cheaper, Not Different (NYSE:GMED) Globus Medical: The Dip Makes It Cheaper, Not Different (NYSE:GMED)
View source ↗ - Newsseekingalpha.com·48d ago·Positive
Globus Medical: 7 Quarters Of Margin Expansion, Priced For None Globus Medical is rated a buy, targeting a 17.5% return over four quarters with a constant 10.56x EV/EBITDA multiple. GMED's base business is compounding faster than headline growth, with international sales rising 18% and gross margin expanding by 200bps, excluding accounting effects. SG&A leverage drove operating margin improvement, while integration of Nevro remains a known, sized, and management-dated drag.
View source ↗ - Newszacks.com·49d ago·Positive
Here is Why Growth Investors Should Buy Globus Medical (GMED) Now Globus Medical (GMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.
View source ↗ - Newszacks.com·55d ago·Positive
Globus Medical (GMED) Upgraded to Strong Buy: Here's Why Globus Medical (GMED) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - Newszacks.com·55d ago·Neutral
GMED vs. ITGR: Which Stock Is the Better Value Option? Investors interested in Medical - Instruments stocks are likely familiar with Globus Medical (GMED) and Integer (ITGR). But which of these two stocks is more attractive to value investors?
View source ↗ - News (Marketaux)insidermonkey.com·58d ago·Neutral
Q2 Earnings Blowouts: 37 Stock That Beat Expectations Globus Medical, In[+341 characters]
View source ↗ - Newsmarketbeat.com·59d ago·Neutral
Globus Medical Q2 Earnings Call Highlights Globus Medical NYSE: GMED reported second-quarter 2026 revenue of $789.6 million, up 6% from a year earlier, as growth in its spine and trauma businesses helped offset declines in enabling technologies and Nevro sales. The company reaffirmed its full-year revenue outlook while raising its adjusted earnings forecast, citing margin expansion and operating leverage in the first half.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $1.20 per share
Typical surprise +20.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$1.34 vs $1.10beat
- Thu, May 7$1.12 vs $0.92beat
- Tue, Feb 24$1.28 vs $1.06beat
- Thu, Nov 6$1.18 vs $0.78beat
- Thu, Aug 7$0.86 vs $0.76beat
- Thu, May 8$0.68 vs $0.74miss
Estimates and results for GMED via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by GMED officers and directors.
- Bought
- —
- Sold
- $23.6m
0 trades
23 trades
- Tobin James Rsold
- Zarrilli Stephen Tsold
- Davidar David Dsold
- Huller Kellysold
- Huller Kellysold
- Kline Kylesold
- Norwalk Leslie Vsold
- Norwalk Leslie Vsold
77 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Cisneroshouse · CA31 · disclosed Sep 11, 2026 (23d later)Buy$15,001 - $50,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Apr 8, 2026 (36d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (34d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (50d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (57d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed May 14, 2025 (35d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed May 19, 2023 (46d later)Buy$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Apr 17, 2023 (42d later)Sell$15,001 - $50,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Mar 17, 2023 (37d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Feb 17, 2023 (37d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 8, 2022 (16d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jul 7, 2022 (10d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 10, 2022 (18d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 10, 2022 (31d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jun 16, 2020 (15d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jun 10, 2020 (13d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Apr 16, 2020 (16d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Mar 10, 2020 (18d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Sep 16, 2019 (52d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA39 · disclosed Aug 19, 2019 (20d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.